What is Protagonist Therapeutics's operating cash flow?

Protagonist Therapeutics (PTGX) reported operating cash flow of -$48.94M in Q1 2026.

How has Protagonist Therapeutics's operating cash flow changed year-over-year?

Protagonist Therapeutics's operating cash flow decreased by 139.0% year-over-year, from $125.36M to -$48.94M.

What does operating cash flow mean?

Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Protagonist Therapeutics PTGX Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers SquibbBMY

$1.1B-43.5%

Eli LillyLLY

$5.33B+220%

AmgenAMGN

$2.19B+57.4%

IncyteINCY

$369.35M+38.8%

AbbVieABBV

$3.83B+134%

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's operating cash flow?: Protagonist Therapeutics (PTGX) reported operating cash flow of -$48.94M in Q1 2026.
How has Protagonist Therapeutics's operating cash flow changed year-over-year?: Protagonist Therapeutics's operating cash flow decreased by 139.0% year-over-year, from $125.36M to -$48.94M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.